<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">MIRVIS, EITAN</style></author><author><style face="normal" font="default" size="100%">MANDAIR, DALVINDER</style></author><author><style face="normal" font="default" size="100%">GARCIA-HERNANDEZ, JORGE</style></author><author><style face="normal" font="default" size="100%">MOHMADUVESH, MULLAN</style></author><author><style face="normal" font="default" size="100%">TOUMPANAKIS, CHRISTOS</style></author><author><style face="normal" font="default" size="100%">CAPLIN, MARTYN</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Role of Interferon-alpha in Patients with Neuroendocrine Tumors: A Retrospective Study</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">6601-6607</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><issue><style face="normal" font="default" size="100%">11</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Interferon alpha (IFNα) is used sparingly in the management of neuroendocrine tumors (NETs) due to toxicity and perceived limited efficacy. Other medical therapeutic options include somatostatin analogues and molecular-targeted agents, as well as chemotherapy and radionuclide targeted-therapy. The aim of the present study was to perform a retrospective analysis of patients treated with IFNα. Patients and Methods: Patients were identified from the NET database. Radiological, biochemical and symptomatic response were assessed. Progression-free survival (PFS), adverse events and toxicities were recorded. Results: Thirty-five patients were treated with IFNα, with a mean age of 60.1 (range=38-85) years; eight patients (23%) withdrew before 3 months, one (3%) had complete response; there was one partial response; 25 patients (71%) had at least three months of stable disease. The median PFS was 25 months. Conclusion: IFNα demonstrated efficacy and was reasonably tolerated. IFNα may still have a role in small-volume diffuse disease, in syndromic patients where there is resistance to somatostatin analogue, or as a bridge to other therapies.</style></abstract></record></records></xml>